Rosatom Scientific Division Experts Present at Nuclear Medicine 2024 Congress
Experts from the Scientific Division of the Rosatom State Corporation spoke in the business program of the III All-Russian Congress with International Participation "Nuclear Medicine - 2024", which ended on December 7 in St. Petersburg. The event brought together researchers, doctors, leading specialists and experts in the field of oncology, radiology, radiology, radiotherapy, X-ray endovascular surgery, cardiology, neurology, endocrinology, radiation hygiene, radiochemistry, radiopharmaceuticals, medical physics and other related specialties.
Representatives of Rosatom took part in the sessions "Radiopharmaceutical drugs: what a radiologist should know about them", "New technologies for obtaining radiopharmaceutical drugs", a round table "Dialogues on painful issues - regulatory framework in nuclear medicine" and others.
As part of the congress, a round table was held by JSC All-Regional Association Izotope (JSC V/O Izotope, part of the Scientific Division of Rosatom) on the topic of "Prospects for opening a new production facility and developing the supply of new precursors and RFLPs to medical organizations."
General Director of JSC V/O Izotope Maksim Kushnarev spoke about meeting the current needs of the Russian healthcare system for radioisotope products and RFLPs and the prospects for developing this area. "Isotope products for medical use, including domestic active pharmaceutical ingredients and RFLPs, are one of the promising areas for the development of Rosatom enterprises. Today, Rosatom scientists are actively involved in the development of new radiopharmaceuticals for high-precision diagnostics and treatment of various oncological, cardiological and other diseases,” he said.
Advisor to the Director General of JSC Rosatom Science Irina Svyato shared with the congress participants global trends in the development of the radiopharmaceutical industry. The speaker said that in recent years, foreign companies have been highly active in the development and use of radiopharmaceutical drugs. The segment of more expensive therapeutic radiopharmaceuticals is growing especially rapidly, outpacing diagnostic drugs. At the same time, most developed countries and BRICS countries have already built or are building large radiopharmaceutical plants. “The world is on the verge of widespread use of radiopharmaceuticals for the treatment of cancer patients in the late stages of the disease, when other methods are ineffective. The scope of application of radiopharmaceuticals is focused not only on oncology, it is expanding. For example, with the help of these drugs, it is possible to successfully diagnose cardiovascular, neurological, mental disorders, including Parkinson's and Alzheimer's diseases. Rosatom has strong competencies in the production of various radionuclides, it remains to take a big step from the supply of raw materials to the development and production of modern targeted RFLPs and ensure the technological independence of the country in the field of nuclear medicine," noted Irina Svyato.
Reference
The III All-Russian Congress with international participation "Nuclear Medicine - 2024" was held on December 6-7 in St. Petersburg. The event is aimed at creating an interdisciplinary platform for discussing a wide range of issues related to the clinical aspects of using modern nuclear medicine technologies, development, manufacturing and production of radiopharmaceuticals, radiation safety issues, as well as legal regulation in nuclear medicine, with the participation of leading Russian experts and specialists from other countries.
Rosatom Scientific Division conducts innovative fundamental and applied research to develop nuclear and non-nuclear technologies (including in the field of closing the nuclear fuel cycle, thermonuclear fusion, nuclear medicine); creates science-intensive technologies both for it and for other industries. It includes 13 research institutes and commercial companies, including SSC RF-IPPE, SSC NIIAR, NPO Luch, Giredmet, Khlopin Radium Institute and others. They have a developed research infrastructure, as well as their own pilot production, capable of fully implementing a scientific idea: from fundamental research to design developments and prototypes. Most of the division's scientific research and development is carried out within the framework of a single industry thematic plan. The division's area of responsibility includes testing, creating high-tech medical equipment, new structural materials. Projects for the commercialization of promising science-intensive technologies are being implemented. www.niirosatom.ru
JSC "V/O "Izotope" is an industry integrator in the field of turnover and promotion of isotope products and the state corporation Rosatom, the official supplier of Rosatom's isotope complex products to the international market and a key supplier of these products to the domestic market. Among the partners of JSC V/O Izotope are 170 foreign companies located in 50 countries, about 600 organizations in Russia, including medical institutions, industrial enterprises and scientific organizations. Today, Rosatom offers the widest range of radioactive and stable isotopes for medical purposes in the world. Based on Rosatom's products, diagnostics and treatment are carried out for more than 2.5 million patients worldwide every year.
JSC V/O Izotope is the first distributor in Russia with an international certificate of compliance of the quality system for the distribution of radiopharmaceutical drugs with the rules of good distribution practice GDP. Today, it supplies about 170 nuclear medicine departments in Russia with products manufactured by Rosatom and Russian partners.
Russia is actively developing scientific cooperation with all interested countries. The implementation of major international projects continues. Rosatom and its divisions are actively involved in this work.
